J.L. Sarasa

Allelic status of chromosome 1 in neoplasms of the nervous system

By using five highly polymorphic markers, the allelic status of chromosome 1 was established in a series of 236 tumors of the nervous system, including all major histologic subtypes: gliomas, meningiomas, neurinomas, neuroblastomas, medulloblastomas, etc. Loss of alleles at 1p was observed at significant frequencies in neuroblastomas (26% of cases), meningiomas (32%), and malignant gliomas (37%) (primarily oligodendrogliomas [94%]). This anomaly was also detected in two of 23 neurinomas, two of three neurofibrosarcomas, one primary lymphoma, and two metastatic tumors of the brain. The analysis of tumors displaying partial 1p deletions suggests the existence of two distinct regions, 1p36 and 1p35-p32, in which loci nonrandomly involved in the development of neurogenic neoplasms might be located.

Mutation analysis of the p73 gene in nonastrocytic brain tumours

Loss of heterozygosity (LOH) involving the distal chromosome 1 p36 region occurs frequently in nonastrocytic brain tumours, but the tumour suppressor gene targeted by this deletion is unknown. p73 is a novel gene that has high sequence homology and similar gene structure to the p53 gene; it has been mapped to 1 p36, and may thus represent a candidate for this tumour suppressor gene. To determine whether p73 is involved in nonastrocytic brain tumour development, we analysed 65 tumour samples including 26 oligodendrogliomas, 4 ependymomas, 5 medulloblastomas, 10 meningiomas, 2 meningeal haemangiopericytomas, 2 neurofibrosarcomas, 3 primary lymphomas, 8 schwannomas and 5 metastatic tumours to the brain, for p73 alterations. Characterization of allelic loss at 1 p36–p35 showed LOH in about 50% of cases, primarily involving oligodendroglial tumours (22 of 26 cases analysed; 85%) and meningiomas (4 of 10; 40%). PCR-SSCP and direct DNA sequencing of exons 2 to 14 of p73 revealed a missense mutation in one primary lymphoma: a G-to-A transition, with Glu291Lys change. 8 additional cases displayed no tumour-specific alterations, as 3 distinct polymorphic changes were identified: a double polymorphic change of exon 5 was found in one ependymoma and both samples derived from an oligodendroglioma, as follows: a G-to-A transition with no change in Pro 146, and a C-to-T variation with no change in Asn 204: a delG at exon 3/+12 position was identified in 4 samples corresponding to 2 oligodendrogliomas, 1 ependymoma and 1 meningioma, and a C-to-T change at exon 2/+10 position was present in a metastatic tumour. Although both LOH at 1 p36 and p73 sequence changes were evidenced in 4 cases, it is difficult to establish a causal role of the p73 variations and nonastrocytic brain tumours development.

Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with tyrosine kinase activity. This report investigates the presence of mutations, amplification and/or over‐expression of the EGFR gene in 86 glial tumours including 44 glioblastomas, 21 anaplastic astrocytomas, and 21 WHO grade II astrocytomas, using polymerase chain reaction/single‐strand conformation polymorphism, semiquantitative reverse‐transcription‐polymerase chain reaction (RT‐PCR) and Southern Blot techniques. Gene amplification values were found in 34 tumours. Amplification levels were not uniform, as the transmembrane region presented lower amplification rates than extra‐ and intracellular domains. For the 19 samples with sufficient available tumour tissue we found over‐expression in 11, and no EGFR mRNA expression in three. Ten cases showed deletion transcripts, and EGFR VIII was identified in all of these cases. One of the cases with EGFR vIII also presented a truncated form, C‐958, while another showed an in frame tandem duplication of exons 18–25. We found 14 cases with sequence/structure gene alterations, including seven on which genomic novel DNA changes were identified: a missense mutation (1052C > T/Ala265Val), an insertion (InsCCC2498/Ins Pro748), three intronic changes (E6 + 72delG, E22–14C > G and E18–109T > C), a new polymorphic variant E12 + 22A > T, and one case that presented a 190 bp insertion, that was produced by the intron‐7–exon‐8 duplication and generated a truncated EGFR with intact exons 1–8 followed by an additional amino acidic sequence: Val‐Ile‐Met‐Trp. These findings corroborate that EGFR is non‐randomly involved in malignant glioma development and that different mutant forms participate in aberrant activation of tyrosine kinase pathways.

Cytogenetic clones in a recurrent neurofibroma

Chromosome studies were performed on a plexiform neurofibroma arising in a probable von Recklinghausens disease patient, who also showed a de novo constitutional reciprocal translocation, t(1;22)(p32;q11). Banding analysis of the metaphases obtained from two primary cultures in vitro showed the presence of five cytogenetic clones, characterized by different chromosomal rearrangements. In addition to t(1;22), marker chromosomes involved pairs 1, 2, 3, 5, 8, 9, 10, 12, 16, and X. These findings suggest a possible polyclonal evolution in this neurofibroma.

Study of the DNA Content by Flow Cytometry and Proliferation in 281 Brain Tumors

In this paper we investigate the distribution of DNA ploidy as well as proliferation rate (S phase of the cell cycle Ki-67 staining) in 281 tumors of the central and peripheral nervous system (87 meningiomas, 75 astrocytomas, 44 nerve sheath tumors, 25 brain metastases, 18 pituitary adenomas, 17 ependymomas, 12 oligodendrogliomas and 3 medulloblastomas) and their correlation with the histopathological grade. Considering all 281 tumors, aneuploidy is the most frequent finding present: 52%. This percentage increases with malignancy: 69% of malignant tumors are aneuploidy. Levels of aneuploidy decrease from brain metastases to pituitary adenoma (92% in brain metastases, 83% in oligodendrogliomas, 59% in nerve sheath tumors, 47% in ependymomas, 40% in astrocytomas, 35% in meningiomas and 33% in pituitary adenomas), but aneuploidy is also found in many benign tumors. With respect to proliferation rate of tumors, S phase above 20% were recorded in the more malignant tumors: brain metastases, oligodendrogliomas, high-grade ependymomas, high grade astrocytomas, and in atypical and malignant meningiomas, but this parameter is not able to distinguish between low and high grade tumors. However, Ki-67 reactivity was equivalent in all histologies with significant differences between low and high grade tumors.

Chromosome 22 heterozygosity is retained in most hyperdiploid and pseudodiploid meningiomas.

Hyperdiploid or pseudodiploid modal chromosome numbers were found characterizing six human meningiomas, and all six tumors were disomic for chromosome 22. The scarce previous reports on the subject suggest that, in these cytogenetic subgroups of meningiomas, duplication of the retained chromosome 22 occurs after the loss of the other member of the pair, thus correlating well with the main characteristic of meningiomas, that is, losses of 22. To verify this question, molecular genetic analyses were performed on DNA pairs from blood and tumoral samples of all six cases, using polymorphic markers for chromosome 22. Restriction fragment length polymorphism studies failed to show any loss of heterozygosity for markers located on this chromosome in all six cases, suggesting that a different mechanism to that previously proposed might take place in the hyperdiploid or pseudodiploid meningiomas; perhaps a submicroscopic involvement (microdeletions or inactivating mutations) of the meningioma locus (both alleles) may result in an effect similar to that produced by monosomy 22 (which probably unmasks recessive mutations on the retained allele), enhancing the development of meningiomas.

Elastosis in meningioma

SummaryA 63-year-old woman underwent a left craniotomy for the removal of a middle cranial fossa meningioma. Microscopically, the tumor showed a transitional and fibroblastic histological pattern. Within the tumoral tissue there were collagenous foci where little eosinophilic masses were found. This component corresponded to elastic material with typical staining properties. Such features disappeared when the histological slides were incubated with elastase. Elastosis is a very uncommon feature observed in meningiomas, with an uncertain significance.